Followers | 377 |
Posts | 17270 |
Boards Moderated | 3 |
Alias Born | 03/07/2014 |
Tuesday, September 16, 2014 7:45:08 PM
Latest 10-Q, Q2 2014, PAGE 27:
"We are seeking to secure sufficient funds to reinitiate enrollment in the MARVEL and REGEN trials. If we successfully secure such funds, we intend to re-engage a contract research organization, or CRO, investigators and certain suppliers to advance such trials. We have initiated and enrolled our first patient in the MIRROR trial in 2013. The trial is very similar to the MARVEL trial but focusses on sites outside the US. We will continue enrollment in the MIRROR trial once we have secured sufficient funds.
"
Remember the MIRROR trial hype PR- the big ole "new" ole phase III? Remember? ONE patient "enrolled"- that's it. Never moved past that. Waiting for "funding", despite the PR hype about it saying it was "FULLY FUNDED" by Bioheart. I guess "fully funded" has different meanings too, like so many things involving this company? If it's now not enrolling, because it's waiting on "funding", then how was it "FULLY FUNDED" clear back in July of 2013? How does that work? How?
http://bioheartinc.com/assets/press/2MirrorTrialInitiatedFinal.pdf
Bioheart, IMO, also never answered these questions from that MIRROR PR-
"Bioheart intends to continue enrollment in the MIRROR trial while hold items are addressed with the FDA."
WHAT is "on hold" by the FDA and why? Were these "hold items" ever resolved?
THOSE are the qty-3 "key" trials they have (phase II/III) and they are not going anywhere, the first two have been stalled, dead in the water for 4 plus yrs now. Which trial(s) plural, are supposedly "moving along"- at least any that matter?
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM